Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Campaign for Access to Essential Medicines, Médecins Sans Frontières, Rue Lausanne 78 CP 116 CH-1211, Geneva 21, Switzerland. margriet.den.boer@msf.org
This review summarizes the current developments in therapy for visceral leishmaniasis. With the recent introduction of new drugs, the main limits in reducing deaths from visceral leishmaniasis are difficulty in diagnosis in the field and health inequality--patients lack of access to treatment. No new drugs are currently in the early stages of development. There are good reasons for the use of combination therapy; to prevent further development of resistance against the limited therapeutic options available.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on